Pauling (Cayman) Ltd Svf Sells 6,000,000 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) major shareholder Pauling (Cayman) Ltd Svf sold 6,000,000 shares of Relay Therapeutics stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $19.40, for a total value of $116,400,000.00. Following the transaction, the insider owned 21,904,963 shares in the company, valued at approximately $424,956,282.20. This represents a 21.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $18.77 on Friday. Relay Therapeutics, Inc. has a 1 year low of $3.52 and a 1 year high of $21.27. The business has a 50-day moving average of $19.27 and a two-hundred day moving average of $14.74. The company has a market capitalization of $4.11 billion, a P/E ratio of -11.96 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million. On average, equities analysts anticipate that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Relay Therapeutics in a research note on Tuesday, May 19th. The Goldman Sachs Group increased their price objective on shares of Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Guggenheim restated a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. Finally, Citizens Jmp upped their target price on shares of Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Institutional Trading of Relay Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RLAY. Alphabet Inc. acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $26,382,000. California State Teachers Retirement System lifted its stake in Relay Therapeutics by 47.9% in the 1st quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock valued at $1,732,000 after purchasing an additional 56,422 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in Relay Therapeutics in the 2nd quarter valued at about $1,323,000. Sanctuary Advisors LLC bought a new position in Relay Therapeutics during the second quarter worth about $1,995,000. Finally, Bank of America Corp DE grew its holdings in Relay Therapeutics by 86.1% during the first quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock worth $19,280,000 after purchasing an additional 896,746 shares during the period. Institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.